A Curve‐Free Method for Phase I Clinical Trials

DOI10.1111/J.0006-341X.2000.00609.XMaRDI QIDQ4667490zbMATH OpenOpenAlexWikidataFDO

Authors Mauro Gasparini, Jeffrey R. Eisele

Publication date 20 April 2005

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1111/j.0006-341x.2000.00609.x

zbMATH Keywords

continual reassessment methodmaximum tolerated dosedose-finding studiesphase I clinical trialtoxicityneutral to the right processproduct-of-beta priors

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Continual reassessment and related dose-finding designs
• Curve-free and model-based continual reassessment method designs
• Continual reassessment method for partial ordering
• On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
• A note on continual reassessment method

Cites work

• A Bayesian nonparametric approach to determining a maximum tolerated dose
• Continual Reassessment Method: A Likelihood Approach
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• On the distribution of the product of independent beta random variables
• Tailfree and neutral random probabilities and their posterior distributions

Cited in

(23)

• Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• EM-type algorithms for computing restricted MLEs in multivariate normal distributions and multivariatet-distributions
• Impact of different model structure and prior distribution in continual reassessment method
• Continual reassessment and related dose-finding designs
• Stochastic approximation and modern model-based designs for dose-finding clinical trials
• Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials
• On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
• A comparative study of the dose-response analysis with application to the target dose estimation
• Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
• Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data
• An application of reinforced urn processes to determining maximum tolerated dose
• Adaptive clinical trial designs for phase I cancer studies
• A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
• Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
• Curve-free and model-based continual reassessment method designs
• Design efficiency in dose finding studies
• The treatment versus experimentation dilemma in dose finding studies
• Bayesian optimal designs for phase I clinical trials
• A simple technique to evaluate model sensitivity in the continual reassessment method
• Continual reassessment method for partial ordering
• Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control

This page was built for publication: A Curve‐Free Method for Phase I Clinical Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4667490)